Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0011812,
umls-concept:C0013030,
umls-concept:C0034693,
umls-concept:C0205464,
umls-concept:C0441655,
umls-concept:C0521390,
umls-concept:C0682770,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1879743,
umls-concept:C1979963,
umls-concept:C2003903,
umls-concept:C2911692
|
pubmed:issue |
3
|
pubmed:dateCreated |
1989-8-17
|
pubmed:abstractText |
1. The effects of dopamine D-1 and D-2 receptor agonists and antagonists were investigated by recording extracellular striatal action potentials in freely moving rats. Dopamine receptor antagonist effects were also evaluated on dexamphetamine-induced excitation of striatal neurons. 2. Striatal neurons responded to SKF 38393, a D-1 agonist, with dose-dependent reductions in activity. At a 2.0 mg/kg dose neuronal activity decreased to 50% of control values. 3. The D-1 antagonist, SCH 23390, at a dose of 4.0 mg/kg decreased striatal neuronal activity by more than 50% and also effectively blocked the effects of 2.5 mg/kg dexamphetamine. 4. LY 171555, a D-2 agonist, at 1.0 or 2.5 mg/kg, did not significantly increase striatal neuronal activity. Although behavioral activation was noted, the neuronal response at the high dose was biphasic with inhibition predominant. 5. The D-2 antagonists haloperidol and sulpiride decreased striatal neuronal activity in a dose-dependent manner and also effectively antagonized the effects of dexamphetamine. The D-2 antagonist, RO 22-1319, at a dose of 2.0 mg/kg completely antagonized increases in striatal neuronal activity after dexamphetamine. 6. These findings suggest that dexamphetamine-induced increases in striatal neuronal activity are due to either stimulation of both D-1 and D-2 receptors, or alternatively, a third dopamine receptor subtype sensitive to both D-1 and D-2 antagonists but not agonists. Furthermore, the concept of specific D-1 and D-2 receptor agonists may require revision as neither SKF 38393 or LY 171555 increased striatal neuronal activity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2,3,4,5-Tetrahydro-7,8-dihydroxy-1-p...,
http://linkedlifedata.com/resource/pubmed/chemical/Benzazepines,
http://linkedlifedata.com/resource/pubmed/chemical/Dextroamphetamine,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Ergolines,
http://linkedlifedata.com/resource/pubmed/chemical/Haloperidol,
http://linkedlifedata.com/resource/pubmed/chemical/Quinpirole,
http://linkedlifedata.com/resource/pubmed/chemical/Sulpiride
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0306-3623
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
295-301
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2568305-2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine,
pubmed-meshheading:2568305-Animals,
pubmed-meshheading:2568305-Behavior, Animal,
pubmed-meshheading:2568305-Benzazepines,
pubmed-meshheading:2568305-Corpus Striatum,
pubmed-meshheading:2568305-Dextroamphetamine,
pubmed-meshheading:2568305-Dopamine Agents,
pubmed-meshheading:2568305-Dopamine Antagonists,
pubmed-meshheading:2568305-Ergolines,
pubmed-meshheading:2568305-Haloperidol,
pubmed-meshheading:2568305-Male,
pubmed-meshheading:2568305-Neurons,
pubmed-meshheading:2568305-Quinpirole,
pubmed-meshheading:2568305-Rats,
pubmed-meshheading:2568305-Sulpiride
|
pubmed:year |
1989
|
pubmed:articleTitle |
Pharmacological activity profiles of dopamine D-1 and D-2 reception agonists and antagonists on striatal neuronal activity and the response to dexamphetamine in freely moving rats.
|
pubmed:affiliation |
Department of Pharmacology, University of Alberta, Edmonton, Canada.
|
pubmed:publicationType |
Journal Article
|